Combination of radiotherapy and sorafenib in recurrent hepatocellular carcinoma: a case report

Yaoru Huang, Shang Wen Chen, Chia-chun Kuo, Jeng-Fong Chiou

Research output: Contribution to journalArticle


In patients with unresectable hepatocellular carcinoma (HCC), radiotherapy is considered for patients with a large tumor burden or tumors with portal vein tumor thrombosis, which is not indicated for operation or transarterial chemoembolization. Sorafenib has proved to be effective as a first-line treatment for locally advanced and metastatic HCC. Preclinical and clinical studies have shown the efficacy of the combined therapeutic effects of radiotherapy (RT) with sorafenib used either concurrently or sequentially. We presented a patient with multiple recurrent HCCs successfully treated with combined RT and sorafenib.
Original languageEnglish
Pages (from-to)155-158
JournalCase Reports in Clinical Pathology
Issue number2
Publication statusPublished - 2014



  • Hepatocellular carcinoma
  • Radiation therapy
  • Sorafenib

Cite this